Analyst Consensus Predictions for Best Buy Co., Inc. (NYSE:BBY), Biogen Idec Inc. (NASDAQ:BIIB)

Research analysts covering Best Buy Co., Inc. (NYSE:BBY) are projecting that the shares reach $45.923 within the next 12-18 months.  This is the consensus number derived from the 13 analyst reports taken into consideration. The most bullish, or aggressive analyst target pins the projected price at $58, while the most bearish, or conservative analyst sees the stock reaching $29.

Broker Rating Update on Best Buy Co., Inc. (NYSE:BBY)

Zacks provides analysts with an Average Broker Rating (or ABR), basing it on sell-side recommendations. Shares of Best Buy Co., Inc. (NYSE:BBY) currently have an ABR of 2.57. This is based on a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.  Moving to earnings estimates, for this current fiscal period, Wall Street analysts have projected that the company will post $0.4 earnings per share. This is the current Zacks consensus EPS which was calculated at the time of writing. Analysts will likely revise their estimates leading in to the actual results date.  

taking a look at the most recent period, which closed on 2017-01-31, Best Buy Co., Inc. reported EPS of $1.95 for a surprise factor of 17.47%, calculated by being $0.29 away from analyst projections.

Investors will be marking their calendars for 2017-05-25, when the company is planning to release their quarterly results.

The Wall Street analysts who cover Biogen Idec Inc. (NASDAQ:BIIB) shares are providing price target projections on the company. They project that the shares will move to $318.571 within the upcoming year. The number they've arrived at is calculated by, long known as a provider of top-notch investment research. From the analysts polled by Zack's Research, the highest estimate stands at $380 and the lowest is at $278 for the stock. This number may be different from what First Call has published for the consensus target estimate. Analysts that routinely cover the company may use varying techniques in order to create a future target price. Because of the different methods that analysts can use, targets may differ greatly between analysts.

Analyst Ratings In View

Zacks provides the average brokerage recommendation (ABR) for thousands of stocks for institutions and retail investors alike. This the calculated average of the actual recommendations (strong buy, hold, sell etc.) made for a given stock. The ABR is typically displayed with decimals (e.g. 1.52) versus the Zacks Rank, which is only shown in whole numbers (e.g. 1, 2, 3, etc.). This simplifies brokerage recommendations, which can become complicated. Biogen Idec Inc. (NASDAQ:BIIB)'s shares currently have an ABR of 1.82. A 1 rating would point to a Strong Buy, and a score of 5 would signify a Strong Sell rating. The average broker rating assists investors by providing them with a general feel for analyst sentiment on company shares.  The success of analyst predictions can be tracked for institutional investors through First Call.  Retail investors can use tools such as TipRanks or Marketbeat in order to track analyst performance. 

During this fiscal period, Street analysts are projecting $4.87 earnings/share. This represents the current Zacks consensus EPS. For the period which closed on 2017-03-31, Biogen Idec Inc. (NASDAQ:BIIB) dialed in an EPS of $5.2, creating a Surprise Factor of 4.63% (the difference between analyst projections and actual numbers). Curious investors will be awaiting 2017-07-20, the date when Biogen Idec Inc. (NASDAQ:BIIB) will release their quarterly results.  A surprise factor in either direction may result in significant stock movement immediately and in the days following the release.  Firms that consistently miss expectations can experience a downtrend over time.  Whereas stocks that consistently outperform analyst expectations, can often see positive stock movement. 

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Comment